Epithelix Sarl specializes in innovative in vitro respiratory solutions, primarily through its advanced tissue models that replicate human airway epithelium. Their flagship product, MucilAir™, is a 3D in vitro model of the human upper airway epithelium, cultured at the air-liquid interface. This model is composed of key cell types, including basal, goblet, and ciliated cells, which are essential for mimicking the physiological functions of the human respiratory system. MucilAir™ is produced with high standards of quality and reproducibility, utilizing low passage human primary cells sourced ethically. The model is designed to maintain its functionality over an extended shelf life, allowing for various applications in research and testing, including evaluations of viral and bacterial infections, inhalation toxicity, and the efficacy of treatments for conditions like cystic fibrosis.

In addition to MucilAir™, Epithelix offers other specialized tissue models such as SmallAir™ for small airway epithelium and AlveolAir™ for alveolar epithelium. These models are complemented by a range of testing services that assess various respiratory conditions and treatments. Epithelix's technologies also include tools for measuring cilia beating frequency and mucociliary clearance, which are critical for understanding respiratory health. Their commitment to quality is underscored by their GIVIMP certification and the provision of certificates of analysis for each tissue batch, ensuring that researchers have reliable and reproducible models for their studies.

Switzerland

Epithelix Sàrl is a Swiss biotech company specialized in human tissue engineering. 
Epithelix provides innovative R&D solutions for the study of human respiratory diseases (e.g. Asthma, COPD, Cystic Fibrosis, etc.) and for inhalation toxicity testing of chemicals, while reducing the number of animal experiments.

Epithelix Sarl

Company Details